在初始使用比克替拉韦、恩曲他滨/丙酚替诺福韦或多替拉韦/恩曲他滨/丙酚替诺福韦治疗后，换用比克替拉韦/恩曲他滨/丙酚替诺福韦复方制剂。
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.
机构信息
Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Orlando Immunology Center, Orlando, Florida.
出版信息
AIDS. 2018 Jul 31;32(12):1723-1725. doi: 10.1097/QAD.0000000000001894.
Abstract
: A phase 2, randomized, active-controlled study of initial antiretroviral therapy with bictegravir or dolutegravir in combination with emtricitabine and tenofovir alafenamide showed excellent efficacy. After 60 weeks of blinded treatment, participants switched to a single-tablet regimen of bictegravir, emtricitabine, and tenofovir alafenamide. Switching maintained viral suppression in all participants who remained on the study through 12 weeks in the open-label phase, and was safe and well tolerated.
摘要
一项关于比克替拉韦或多替拉韦联合恩曲他滨和替诺福韦艾拉酚胺作为初始抗逆转录病毒治疗的 2 期、随机、阳性对照研究显示出了极好的疗效。在盲法治疗 60 周后，参与者转为服用比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺单片复方制剂。在开放标签期的 12 周内，所有继续参与研究的参与者均维持病毒抑制，且转换是安全且耐受良好的。
相似文献
1
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.在初始使用比克替拉韦、恩曲他滨/丙酚替诺福韦或多替拉韦/恩曲他滨/丙酚替诺福韦治疗后，换用比克替拉韦/恩曲他滨/丙酚替诺福韦复方制剂。
AIDS. 2018 Jul 31;32(12):1723-1725. doi: 10.1097/QAD.0000000000001894.
2
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.从多替拉韦加阿巴卡韦和拉米夫定转换为固定剂量比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺治疗病毒学抑制的 HIV-1 成人患者：一项随机、双盲、多中心、活性对照、3 期、非劣效性临床试验的 48 周结果。
Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18.
3
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨与丙酚替诺福韦二吡呋酯复方片剂与多替拉韦加拉米夫定和丙酚替诺福韦二吡呋酯用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1490）：一项随机、双盲、多中心、3 期、非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.
4
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺与多替拉韦、阿巴卡韦和拉米夫定用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1489）：一项双盲、多中心、3 期、随机、对照非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.
5
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.固定剂量复方比克替拉韦、恩曲他滨和丙酚替诺福韦艾拉酚胺与含多替拉韦方案治疗初治人类免疫缺陷病毒 1 型感染：两项随机、双盲、多中心、Ⅲ期、非劣效性临床试验的 144 周结果。
Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0.
6
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨和丙酚替诺福韦艾拉酚胺与多替拉韦、阿巴卡韦和拉米夫定用于初治 HIV-1 感染：来自一项随机、双盲、多中心、3 期、非劣效性试验的第 96 周结果。
Lancet HIV. 2019 Jun;6(6):e355-e363. doi: 10.1016/S2352-3018(19)30077-3. Epub 2019 May 5.
7
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨与丙酚替诺福韦二吡呋酯固定剂量复方片与多替拉韦加拉米夫定用于治疗人类免疫缺陷病毒 1 型感染的初治：96 周随机、双盲、多中心、3 期、非劣效性试验结果。
Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5.
8
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.比克替拉韦与多替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯用于 HIV-1 感染初始治疗的双盲、随机、2 期临床试验
Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15.
9
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.固定剂量复方双替格瑞韦、恩曲他滨和替诺福韦艾拉酚胺在青少年和儿童 HIV 感染者中的应用：一项单臂、开放标签、多中心、2/3 期临床试验的第 48 周结果。
Lancet Child Adolesc Health. 2021 Sep;5(9):642-651. doi: 10.1016/S2352-4642(21)00165-6. Epub 2021 Jul 22.
10
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.在病毒学抑制的 HIV 儿童患者（年龄 2 岁及以上）中，双替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯复方制剂的药代动力学和安全性：一项 2/3 期、开放标签、单臂研究。
Lancet HIV. 2024 May;11(5):e300-e308. doi: 10.1016/S2352-3018(23)00327-2. Epub 2024 Apr 12.
引用本文的文献
1
INSTIs-centered antiviral regimens for first-line treatment of HIV/AIDS: a network meta-analysis and cost-effectiveness analysis.以整合酶链转移抑制剂（INSTIs）为中心的抗逆转录病毒治疗方案用于HIV/AIDS一线治疗：一项网状Meta分析和成本效益分析。
BMC Infect Dis. 2025 Apr 25;25(1):604. doi: 10.1186/s12879-025-10858-x.
2
Changes in blood lipid levels and influencing factors among treatment-naïve adult male HIV/AIDS patients following BIC/FTC/TAF vs . 3TC+EFV+TDF.初治成年男性 HIV/AIDS 患者接受 BIC/FTC/TAF 与 3TC+EFV+TDF 治疗后血脂水平变化及影响因素分析。
Chin Med J (Engl). 2024 Jun 20;137(12):1447-1452. doi: 10.1097/CM9.0000000000003147. Epub 2024 May 30.
3
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.HIV-1 整合酶链转移抑制剂的比较临床药代动力学和药效学：更新综述。
Clin Pharmacokinet. 2020 Sep;59(9):1085-1107. doi: 10.1007/s40262-020-00898-8.
本文引用的文献
1
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺与多替拉韦、阿巴卡韦和拉米夫定用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1489）：一项双盲、多中心、3 期、随机、对照非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.
2
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.比克替拉韦与多替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯用于 HIV-1 感染初始治疗的双盲、随机、2 期临床试验
Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15.
3
Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults.比克替拉韦作为10天单药疗法在HIV-1感染成人中的抗病毒活性、安全性和药代动力学
J Acquir Immune Defic Syndr. 2017 May 1;75(1):61-66. doi: 10.1097/QAI.0000000000001306.
4
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.比克替拉韦（GS-9883）的抗病毒活性，一种新型强效HIV-1整合酶链转移抑制剂，具有改善的耐药性谱。
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. doi: 10.1128/AAC.01474-16. Print 2016 Dec.
Zotero 插件